Key Highlights
- New Ultrasound Device for Cancer Treatment: The Edison Histotripsy System utilizes micro-bubbles for non-invasive liver cancer treatment.
- First Deployment and Funding: One of the first four systems worldwide, funded by a $500,000 grant from the GI Research Foundation’s CA CURE initiative.
- Future Potential: Approved for liver tumors with potential for treating other gastrointestinal and abdominal cancers.
Source: Newswire
Notable Quotes
- “Histotripsy is a new category of treatment,” – Dr. Osman Ahmed, Interventional Radiologist and Associate Professor at University of Chicago
- “This world would look very different without physicians like Os and his team.” – Mike Blue, CEO at HistoSonics
- “The GI Research Foundation has a legacy of funding high risk-high reward and innovative science,” – Dr. David Rubin, Joseph B. Kirsner Professor of Medicine and Chief of the Section of Gastroenterology, Hepatology and Nutrition at University of Chicago Medicine
SoH's Take
The introduction of the Edison Histotripsy System at the University of Chicago’s medical center marks a significant advancement in cancer treatment, particularly for liver cancer patients. Its innovative approach, leveraging micro-bubble technology for non-invasive treatment, not only enhances patient safety by reducing the risks associated with surgery or thermal treatments but also signifies a shift towards more precise and less invasive cancer therapies.
The system’s early adoption and support by the GI Research Foundation underscore the critical role of targeted funding in accelerating the availability of cutting-edge medical technologies. The potential expansion of its application to other gastrointestinal and abdominal cancers further highlights its versatility and the promising future of histotripsy in cancer treatment.
